THRX up +1.57% percent Today $THRX High is at 13.6
Post# of 74540
Posted On: 11/19/2014 1:59:18 PM
THRX up +1.57% percent Today $THRX High is at 13.61 and the Low 13.17 with current volume of 79,966.
Recent News posted below.
Theravance THRX other info.
http://investorshangout.com/Theravance-THRX-55637/
THRX Theravance Recent Headline News
Patient recruitment complete in "real-world" COPD study
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 7:32AM CST
THRX: 13.58 (+0.23), GSK: 46.41 (+0.13)
Theravance Earnings Review: 18 Days after Announcement Shares Down 18.4% (THRX)
Comtex SmarTrend(R) - Mon Nov 17, 4:04PM CST
When Theravance (NASDAQ:THRX) reported earnings two weeks ago on October 30th, 2014, analysts, on average, expected the company to report a loss of $0.13 on sales of $6.9 million. Theravance actually reported a loss of $0.19 per share on sales of $999.0 thousand, missing EPS estimates by $0.06 and missing revenue estimates by $5.9 million. Shares of Theravance have slipped from $16.21 to $13.23, representing a loss of 18.4%, since the company reported earnings 18 days ago.
THRX: 13.58 (+0.23)
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST
OCN: 21.24 (+0.19), KOS: 9.44 (+0.05), KIN: 8.96 (+0.05), VSAT: 65.64 (+0.10), RFMD: 13.69 (-0.06), EBAY: 55.03 (-0.35), TQNT: 22.85 (-0.08), IDIX: 24.50 (+0.05), SEMI: 16.65 (-0.01), VRTV: 50.69 (+2.30), THRX: 13.58 (+0.23), TBPH: 16.50 (+0.04), IMOS: 20.70 (-0.91), ELOS: 9.90 (-0.03), MU: 32.75 (-0.12), AR: 52.98 (+0.83), NCQ: 0.69 (unch), PBF: 28.38 (+0.72), LNG: 72.71 (+0.95), ATRA: 26.63 (+0.28), KERX: 15.26 (-0.28), NG: 2.95 (-0.08), AOI: 1.89 (-0.01), FWP: 21.39 (+0.25), BYD: 11.70 (-0.04), ALDW: 17.67 (+0.11), SUNE: 21.39 (-0.09), MRK: 59.55 (-0.34), AVEO: 0.99 (+0.04), AIG: 54.03 (+0.14)
Update: Theravance Reveals Interesting Bits Of Information At CS Conference
Early Retiree - at Seeking Alpha - Fri Nov 14, 10:53AM CST
THRX: 13.58 (+0.23), TBPH: 16.50 (+0.04), GSK: 46.41 (+0.13)
Shares of THRX Down 51.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 14, 9:38AM CST
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 4 months, Theravance has returned 51.85% as of today's recent price of $13.16.
THRX: 13.58 (+0.23)
Theravance's (THRX) CEO Mike Aguiar on Credit Suisse Healthcare Conference - Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 2:38PM CST
THRX: 13.58 (+0.23)
When Is It Time To Accumulate Theravance?
Chris Lau - at Seeking Alpha - Tue Nov 11, 10:50AM CST
MRK: 59.55 (-0.34), AZN: 75.42 (+1.44), THRX: 13.58 (+0.23), TBPH: 16.50 (+0.04), GSK: 46.40 (+0.12)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.55 (-0.34), AZN: 75.42 (+1.44), AMGN: 162.74 (+0.50), TEVA: 57.22 (-0.01), THRX: 13.58 (+0.23), GSK: 46.40 (+0.12), SNY: 48.34 (-0.02), REGN: 416.75 (+3.53), NVS: 95.75 (+0.17)
Theravance Biopharma Q3 Loss Widens Y/Y, Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:20AM CST
Theravance Biopharma reported a third-quarter 2014 loss of $1.72 per share.
AMAG: 35.69 (+0.35), TBPH: 16.50 (+0.04), GSK: 46.40 (+0.12), THRX: 13.58 (+0.23)
Shares of THRX Down 47.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 07, 9:10AM CST
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 4 months, Theravance has returned 47.93% as of today's recent price of $14.23.
THRX: 13.58 (+0.23)
5 Stocks With Big Insider Buying in November: NuStar, Huntsman and More
at The Street - Thu Nov 06, 11:45AM CST
Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.
SCCO: 29.83 (-0.49), WRLD: 78.19 (+1.12), NS: 59.40 (-0.40), THRX: 13.58 (+0.23), HUN: 26.02 (-0.31)
Theravance to Present at Two Upcoming Investor Conferences in November
Marketwired - Wed Nov 05, 3:08PM CST
Theravance, Inc. (NASDAQ: THRX) today announced Michael W. Aguiar, President and Chief Executive Officer of Theravance, will be presenting at two upcoming investor conferences in November.
THRXV: 28.00 (+7.07), THRX: 13.58 (+0.23)
Real Money's Brian Sozzi: A Primer on Investing in Retail Stocks
at The Street - Wed Nov 05, 11:38AM CST
Some thoughts on the outlook of the retail sector and what to look for before you invest.
COH: 35.52 (+0.22), TJX: 61.84 (+0.20), NKE: 97.00 (+0.53), TGT: 72.12 (+4.61), WMT: 85.13 (+1.34), HBI: 111.75 (+1.32), THRX: 13.58 (+0.23), KORS: 72.87 (-0.06), GPS: 39.40 (+0.05), RL: 178.76 (+2.20), LULU: 45.50 (+0.70)
InsiderInsights.com Daily Round Up 11/4/14: UFI, SABA, CCI
InsiderInsights - at Seeking Alpha - Wed Nov 05, 8:31AM CST
CCI: 80.67 (+0.15), CBG: 32.94 (-0.20), HGG: 6.11 (+0.07), LLY: 67.11 (-0.67), BA: 132.01 (+1.35), MAR: 76.73 (-0.21), QNST: 4.31 (-0.09), OZRK: 35.95 (+0.08), APO: 23.04 (-0.30), STAA: 8.69 (-0.01), AMBR: 11.19 (-0.05), FSAM: 14.53 (-0.23), WRLD: 78.19 (+1.12), CPLA: 69.38 (+0.59), THRX: 13.58 (+0.23), MSFT: 48.16 (-0.58), UFI: 27.29 (+0.17), AN: 58.23 (+0.50), CRM: 61.36 (-1.11)
FDA accepts BI's Spiriva NDA for asthma
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 12:06PM CST
AZN: 75.42 (+1.44), TEVA: 57.22 (-0.01), GSK: 46.40 (+0.12), THRX: 13.58 (+0.23), SNY: 48.34 (-0.02), REGN: 416.75 (+3.53), NVS: 95.75 (+0.17)
7 Old Dividend Dogs Of Healthcare Aim At 11% To 30.5% October Upsides
Fredrik Arnold - at Seeking Alpha - Mon Nov 03, 11:21AM CST
KND: 20.53 (+0.53), VIVO: 16.04 (-0.10), PETS: 13.35 (-0.15), PFE: 30.37 (-0.22), GSK: 46.40 (+0.12), MR: 30.93 (+0.17), SEM: 13.78 (-0.06), PDLI: 7.94 (-0.03), SNN: 34.14 (+0.36), AZN: 75.42 (+1.44), MRK: 59.55 (-0.34), STJ: 63.84 (-1.11), TRIB: 17.10 (-0.15), ABBV: 65.59 (-0.46), THRX: 13.58 (+0.23), SNY: 48.34 (-0.02)
Theravance (THRX) Falls on Wider-than-Expected Loss in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:10AM CST
Theravance reported third-quarter 2014 loss of 19 cents per share.
AMAG: 35.69 (+0.35), TBPH: 16.50 (+0.04), GSK: 46.40 (+0.12), THRX: 13.58 (+0.23)
Bayer Q3 Earnings Grow Y/Y on New Product Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:00AM CST
Bayer's (BAYRY) earnings during the third quarter of 2014 came in at roughly $1.79 per share.
MRK: 59.55 (-0.34), AMAG: 35.69 (+0.35), THRX: 13.58 (+0.23)
Update: GSK Starts Promoting Theravance Drugs More Actively
Early Retiree - at Seeking Alpha - Sat Nov 01, 7:42AM CDT
THRX: 13.58 (+0.23), GSK: 46.40 (+0.12)
More on Theravance Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 1:03PM CDT
THRX: 13.58 (+0.23)
Recent News posted below.
Theravance THRX other info.
http://investorshangout.com/Theravance-THRX-55637/
THRX Theravance Recent Headline News
Patient recruitment complete in "real-world" COPD study
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 7:32AM CST
THRX: 13.58 (+0.23), GSK: 46.41 (+0.13)
Theravance Earnings Review: 18 Days after Announcement Shares Down 18.4% (THRX)
Comtex SmarTrend(R) - Mon Nov 17, 4:04PM CST
When Theravance (NASDAQ:THRX) reported earnings two weeks ago on October 30th, 2014, analysts, on average, expected the company to report a loss of $0.13 on sales of $6.9 million. Theravance actually reported a loss of $0.19 per share on sales of $999.0 thousand, missing EPS estimates by $0.06 and missing revenue estimates by $5.9 million. Shares of Theravance have slipped from $16.21 to $13.23, representing a loss of 18.4%, since the company reported earnings 18 days ago.
THRX: 13.58 (+0.23)
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST
OCN: 21.24 (+0.19), KOS: 9.44 (+0.05), KIN: 8.96 (+0.05), VSAT: 65.64 (+0.10), RFMD: 13.69 (-0.06), EBAY: 55.03 (-0.35), TQNT: 22.85 (-0.08), IDIX: 24.50 (+0.05), SEMI: 16.65 (-0.01), VRTV: 50.69 (+2.30), THRX: 13.58 (+0.23), TBPH: 16.50 (+0.04), IMOS: 20.70 (-0.91), ELOS: 9.90 (-0.03), MU: 32.75 (-0.12), AR: 52.98 (+0.83), NCQ: 0.69 (unch), PBF: 28.38 (+0.72), LNG: 72.71 (+0.95), ATRA: 26.63 (+0.28), KERX: 15.26 (-0.28), NG: 2.95 (-0.08), AOI: 1.89 (-0.01), FWP: 21.39 (+0.25), BYD: 11.70 (-0.04), ALDW: 17.67 (+0.11), SUNE: 21.39 (-0.09), MRK: 59.55 (-0.34), AVEO: 0.99 (+0.04), AIG: 54.03 (+0.14)
Update: Theravance Reveals Interesting Bits Of Information At CS Conference
Early Retiree - at Seeking Alpha - Fri Nov 14, 10:53AM CST
THRX: 13.58 (+0.23), TBPH: 16.50 (+0.04), GSK: 46.41 (+0.13)
Shares of THRX Down 51.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 14, 9:38AM CST
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 4 months, Theravance has returned 51.85% as of today's recent price of $13.16.
THRX: 13.58 (+0.23)
Theravance's (THRX) CEO Mike Aguiar on Credit Suisse Healthcare Conference - Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 2:38PM CST
THRX: 13.58 (+0.23)
When Is It Time To Accumulate Theravance?
Chris Lau - at Seeking Alpha - Tue Nov 11, 10:50AM CST
MRK: 59.55 (-0.34), AZN: 75.42 (+1.44), THRX: 13.58 (+0.23), TBPH: 16.50 (+0.04), GSK: 46.40 (+0.12)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.55 (-0.34), AZN: 75.42 (+1.44), AMGN: 162.74 (+0.50), TEVA: 57.22 (-0.01), THRX: 13.58 (+0.23), GSK: 46.40 (+0.12), SNY: 48.34 (-0.02), REGN: 416.75 (+3.53), NVS: 95.75 (+0.17)
Theravance Biopharma Q3 Loss Widens Y/Y, Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:20AM CST
Theravance Biopharma reported a third-quarter 2014 loss of $1.72 per share.
AMAG: 35.69 (+0.35), TBPH: 16.50 (+0.04), GSK: 46.40 (+0.12), THRX: 13.58 (+0.23)
Shares of THRX Down 47.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 07, 9:10AM CST
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 4 months, Theravance has returned 47.93% as of today's recent price of $14.23.
THRX: 13.58 (+0.23)
5 Stocks With Big Insider Buying in November: NuStar, Huntsman and More
at The Street - Thu Nov 06, 11:45AM CST
Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.
SCCO: 29.83 (-0.49), WRLD: 78.19 (+1.12), NS: 59.40 (-0.40), THRX: 13.58 (+0.23), HUN: 26.02 (-0.31)
Theravance to Present at Two Upcoming Investor Conferences in November
Marketwired - Wed Nov 05, 3:08PM CST
Theravance, Inc. (NASDAQ: THRX) today announced Michael W. Aguiar, President and Chief Executive Officer of Theravance, will be presenting at two upcoming investor conferences in November.
THRXV: 28.00 (+7.07), THRX: 13.58 (+0.23)
Real Money's Brian Sozzi: A Primer on Investing in Retail Stocks
at The Street - Wed Nov 05, 11:38AM CST
Some thoughts on the outlook of the retail sector and what to look for before you invest.
COH: 35.52 (+0.22), TJX: 61.84 (+0.20), NKE: 97.00 (+0.53), TGT: 72.12 (+4.61), WMT: 85.13 (+1.34), HBI: 111.75 (+1.32), THRX: 13.58 (+0.23), KORS: 72.87 (-0.06), GPS: 39.40 (+0.05), RL: 178.76 (+2.20), LULU: 45.50 (+0.70)
InsiderInsights.com Daily Round Up 11/4/14: UFI, SABA, CCI
InsiderInsights - at Seeking Alpha - Wed Nov 05, 8:31AM CST
CCI: 80.67 (+0.15), CBG: 32.94 (-0.20), HGG: 6.11 (+0.07), LLY: 67.11 (-0.67), BA: 132.01 (+1.35), MAR: 76.73 (-0.21), QNST: 4.31 (-0.09), OZRK: 35.95 (+0.08), APO: 23.04 (-0.30), STAA: 8.69 (-0.01), AMBR: 11.19 (-0.05), FSAM: 14.53 (-0.23), WRLD: 78.19 (+1.12), CPLA: 69.38 (+0.59), THRX: 13.58 (+0.23), MSFT: 48.16 (-0.58), UFI: 27.29 (+0.17), AN: 58.23 (+0.50), CRM: 61.36 (-1.11)
FDA accepts BI's Spiriva NDA for asthma
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 12:06PM CST
AZN: 75.42 (+1.44), TEVA: 57.22 (-0.01), GSK: 46.40 (+0.12), THRX: 13.58 (+0.23), SNY: 48.34 (-0.02), REGN: 416.75 (+3.53), NVS: 95.75 (+0.17)
7 Old Dividend Dogs Of Healthcare Aim At 11% To 30.5% October Upsides
Fredrik Arnold - at Seeking Alpha - Mon Nov 03, 11:21AM CST
KND: 20.53 (+0.53), VIVO: 16.04 (-0.10), PETS: 13.35 (-0.15), PFE: 30.37 (-0.22), GSK: 46.40 (+0.12), MR: 30.93 (+0.17), SEM: 13.78 (-0.06), PDLI: 7.94 (-0.03), SNN: 34.14 (+0.36), AZN: 75.42 (+1.44), MRK: 59.55 (-0.34), STJ: 63.84 (-1.11), TRIB: 17.10 (-0.15), ABBV: 65.59 (-0.46), THRX: 13.58 (+0.23), SNY: 48.34 (-0.02)
Theravance (THRX) Falls on Wider-than-Expected Loss in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:10AM CST
Theravance reported third-quarter 2014 loss of 19 cents per share.
AMAG: 35.69 (+0.35), TBPH: 16.50 (+0.04), GSK: 46.40 (+0.12), THRX: 13.58 (+0.23)
Bayer Q3 Earnings Grow Y/Y on New Product Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:00AM CST
Bayer's (BAYRY) earnings during the third quarter of 2014 came in at roughly $1.79 per share.
MRK: 59.55 (-0.34), AMAG: 35.69 (+0.35), THRX: 13.58 (+0.23)
Update: GSK Starts Promoting Theravance Drugs More Actively
Early Retiree - at Seeking Alpha - Sat Nov 01, 7:42AM CDT
THRX: 13.58 (+0.23), GSK: 46.40 (+0.12)
More on Theravance Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 1:03PM CDT
THRX: 13.58 (+0.23)
(0)
(0)Scroll down for more posts ▼